Blockade of ALCAM reduced the transmigration of CD4+ lymphocytes and monocytes across the BBB and reduced the severity and delayed the time of onset of experimental autoimmune encephalomyelitis in animal models, highlighting the potential usefulness of ALCAM as a therapeutic target in multiple sclerosis (86). This evidence concerns the gene ALCAM and experimental autoimmune encephalomyelitis.